Medical/Pharmaceuticals
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...
2026-02-27 04:34
4774
SK bioscience, IDT Biologika and Vaxxas Selected for Next-Generation Influenza Vaccine development Financed by the European Union
* SK–IDT–Vaxxas consortium establishes strategic entry point for high-density microarray patch (HD-MAP) vaccines inEurope to improve vaccine performance and access. * Parallel development of high-immunogenicity HD-MAP vaccines for seasonal and pandemic influenza threats. INCHEON, South Korea,...
2026-02-26 21:00
4860
Health Awareness Week Underscores the Importance of Respiratory Health
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- As Health Awareness Week brings focus
to preventive care and chronic condition management,VARON
2026-02-26 16:42
3399
Sanyou Biopharmaceuticals Announces New Strategic Investor; Liferiver Biotech Increases Its Stake, and Gree Group's Yanghe Investment Joins as a Strategic Shareholder
SHANGHAI, Feb. 24, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio"), a biotech company powered by super-trillion-molecule libraries and AI-driven technologies, today announced the completion of a significant equity restructuring. The shares previously held by Hai...
2026-02-24 22:00
4610
"Would You Clone Yourself for a Cure?" Clonell Unveils White Paper on Fundamental Cures for 34 Incurable Diseases Using 'Human Cloning' Technology
Harnessing the vitality of a clone while neutralizing ethical controversies through a breakthrough 'Therapeutic Cloning' protocol—ushering in a new era of regenerative medicine to conquer cancer, Alzheimer's, and aging. YONGIN, South Korea, Feb. 23, 2026 /PRNewswire/ -- Human cloning has long be...
2026-02-23 21:40
3043
iRegene Hits Dual Global Firsts: U.S. Patient Dosed in Phase IIa for NouvNeu001 in Parkinson's and First Enrollment in China's Randomized MSA Trial for NouvNeu004
CHENGDU, China, Feb. 23, 2026 /PRNewswire/ -- The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. andChina. Concurrently, the company's "AI + Chemical Induction" platform saw its...
2026-02-23 21:00
4105
Formosa Pharmaceuticals Announces Licensing Agreement with Arrotex, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, Feb. 23, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Arrotex Pharmaceuticals Pty Ltd. ("Arrotex"), for exclusive rights to the commercialization of clobetasol propio...
2026-02-23 14:00
4516
CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC
* Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the second indication approved for the product in the UK. ...
2026-02-23 08:10
4238
Datasea Announces Foundational Research Breakthrough in Ultrasonic-Enhanced Nanoscale Precision Control
Establishing an Engineering-Level Core Technology for Next-Generation Semiconductor Manufacturing Applications BEIJING, Feb. 18, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based technology company specializing in acoustic high-tech solutions and 5G+AI ...
2026-02-18 22:30
7098
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...
2026-02-16 22:03
7326
CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial
* CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)to initiate a Phase II clinical trial inpatients with advanced solid tumors. This marks a significant milestone in the global development of thi...
2026-02-16 08:10
6289
HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer
First SIRPα-IgG4 Fc Fusion Protein Granted Orphan Status in Gastric Cancer TAIPEI, SHANGHAI and SAN FRANCISCO, Feb. 13, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases,...
2026-02-13 14:04
5840
Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer
SAN FRANCISCO and SUZHOU, China, Feb. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2026-02-13 08:00
5589
Datasea Reports Second Fiscal Quarter 2026 Results
Gross Profit Increased 284.4% Year-over-Year and Gross Margin Increases 730 Basis Points to 8.8% BEIJING, Feb. 12, 2026 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based technology enterprise engaged in acoustic technologies and 5G+AI multimodal digitalizati...
2026-02-12 22:20
12869
Sanyou Biopharmaceuticals Lang Guojun: Making Innovative Biologics R&D Easier for Clients Worldwide
Tagline: Empowering Global Innovative Biologics R&D through Ecosystem Strength SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- On February 8, at the 2026 China New Drug Source Innovation Forum inShanghai, Lang Guojun, Founder & CEO of Sanyou Biopharmaceuticals, shared the story of a vision that began ten...
2026-02-12 22:00
5284
J INTS BIO Reports Fourth-Generation EGFR Inhibitor JIN-A02 in Clinical Cancer Research
SEOUL, South Korea, Feb. 12, 2026 /PRNewswire/ -- J INTS BIO, Inc. announced that research findings on its investigational fourth-generation EGFR tyrosine kinase inhibitor (TKI), JIN-A02, have been published in Clinical Cancer Research, a leading oncology journal published by the American Associa...
2026-02-12 15:01
4679
WuXi Vaccines Receives Brazil's ANVISA GMP Certification
SUZHOU, China, Feb. 11, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that it has received Good Manufacturing Practices (GMP) certification for its fill and finish f...
2026-02-12 11:48
4828
Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications
HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These i...
2026-02-11 17:01
5857
PharmaResearch Announces Supply Agreement for Rejuran in Brazil
SEONGNAM, South Korea, Feb. 11, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEOJihoon Sohn), a leading regenerative medicine company, announced that it has entered into an exclusive supply agreement for Rejuran with DermaDream, a Brazilian aesthetic company, as part of its preparations for ent...
2026-02-11 14:54
4234
On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully
SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- As China's new drug R&D enters the "deep waters" of homogeneous competition, the path for followers has become increasingly crowded. Target congestion, rising costs, and intensifying global races have pushed the traditional follow-on model to its limits. Th...
2026-02-10 21:07
5514
Week's Top Stories
Most Reposted
Global virtual travel card program launched by Visa and Trip.com to make travel payments simpler and more seamless in Asia Pacific
[Picked up by 331 media titles]
2026-03-11 11:08The Mastercard Collection: Savor the Extraordinary with Mastercard's Asia Gourmet Circle Program
[Picked up by 295 media titles]
2026-03-12 09:00TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health
[Picked up by 295 media titles]
2026-03-09 21:36
PDG Targets USD 5 Billion Debt Raise
[Picked up by 295 media titles]
2026-03-11 10:00Progress Software Highlights Load Balancing as a Strategic Imperative for APAC Digital Infrastructure Resilience
[Picked up by 294 media titles]
2026-03-10 09:00
